The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×5•Originally published 16 April 2026•Updated 18 April 2026•

1 min read

Valuation Gaps Widen Between Vistra, Merck, and Verisk Despite Recent Gains

A red downward arrow points to a shattered, glowing object labeled 'RP1' amidst an explosion, with '-75%' and 'DENIED' visible.

Key Facts

1Vistra Corp (VST) is overvalued by 24.6% relative to its GF Value, with $1.6 million in insider selling.

about 2 months ago

Version History

Version 5about 2 months ago

What changed: The story was updated to include technical indicators for Vistra Corp (VST), noting its breakout above the 50-day SMA and 43% annual gain driven by clean energy demand.

Version 4about 2 months ago

What changed: The analysis was updated to include PulteGroup Inc (PHM), identifying it as overvalued following a 5% price surge, despite its high fundamental score and recent insider selling activity.

Version 3about 2 months ago

What changed: The analysis was expanded to include Weyerhaeuser Co (WY) as an undervalued asset with positive insider buying signals.

Version 2about 2 months ago

What changed: The analysis was expanded to include Merck & Co Inc (MRK), highlighting its 'fairly valued' status and heavy insider selling exceeding $40 million.

Version 1about 2 months ago

What changed: The report was expanded to include a valuation analysis of The Mosaic Co (MOS), highlighting its recent gains and low growth ranking in comparison to Vistra and Verisk.

A recent financial analysis highlights a sharp divergence in fundamental valuations across Vistra Corp (VST), Merck & Co (MRK), and Verisk Analytics (VRSK). Vistra Corp (VST) is showing strong technical momentum, trading above its 50-day SMA at $165.53 with a 43% year-over-year gain driven by clean-power demand and hedging strategies. Meanwhile, PulteGroup (PHM) is now identified as overvalued by 7.6% despite an exceptional GF Score of 96/100, accompanied by significant insider selling. Merck continues to see heavy insider selling totaling $40.1 million, while Verisk and Weyerhaeuser remain undervalued relative to their intrinsic fair values. These updates underscore a growing disconnect between short-term price momentum, such as Vistra's technical breakout, and long-term valuation indicators across the sector.